1. Remote Patient-Reported Outcomes and Activity Monitoring to Improve Patient-Clinician Communication Regarding Symptoms and Functional Status: A Randomized Controlled Trial.
- Author
-
Parikh, Ravi B., Schriver, Emily, Ferrell, William J., Wakim, Jonathan, Williamson, Joelle, Khan, Neda, Kopinsky, Michael, Balachandran, Mohan, Gabriel, Peter E., Schuchter, Lynn M., Patel, Mitesh S., Shulman, Lawrence N., and Manz, Christopher R.
- Subjects
PUBLIC health surveillance ,KRUSKAL-Wallis Test ,FUNCTIONAL status ,HEALTH outcome assessment ,TERTIARY care ,LUNG tumors ,RANDOMIZED controlled trials ,GASTROINTESTINAL tumors ,CANCER patients ,SURVEYS ,T-test (Statistics) ,QUALITY assurance ,COMMUNICATION ,SCALE analysis (Psychology) ,DESCRIPTIVE statistics ,HOSPITAL care ,RESEARCH funding ,PATIENT-professional relations ,TUMORS ,STATISTICAL sampling ,DATA analysis software ,DEATH ,TELEMEDICINE ,CANCER patient medical care ,PALLIATIVE treatment ,SYMPTOMS - Abstract
PURPOSE Routine collection of patient-generated health data (PGHD) may promote earlier recognition of symptomatic and functional decline. This trial assessed the impact of an intervention integrating remote PGHD collection with patient nudges on symptom and functional status understanding between patients with advanced cancer and their oncology team. METHODS This three-arm randomized controlled trial was conducted from November 19, 2020, to December 17, 2021, at a large tertiary oncology practice. We enrolled patients with stage IV GI and lung cancers undergoing chemotherapy. Over 6 months, patients in two intervention arms received PROStep--weekly text message--based symptom surveys and passive activity monitoring using a wearable accelerometer. PGHD were summarized in dashboards given to patients' oncology team before appointments. One intervention arm received an additional text-based active choice prompt to discuss worsening symptoms or functional status with their clinician. Control patients did not receive PROStep. The coprimary outcomes patient perceptions of oncology team symptom and functional understanding at 6 months were measured on a 1-5 Likert scale (5 = high understanding). RESULTS One hundred eight patients enrolled: 55% male, 81% White, and 77% had GI cancers. Patient-reported clinician understanding did not differ between control and intervention arms for symptoms (4.5 v 4.5; P = .87) or functional status (4.5 v 4.3; P = .31). In the intervention arms, combined patient adherence to weekly symptom reports and daily activity monitoring was 64% and 53%, respectively. Intervention patients in the PROStep versus PROStep + active choice arms reported low burden from wearing the accelerometer (mean burden [standard deviation], 2.7 [1.3] v 2.1 [1.3]; P = .15) and completing surveys (2.1 [1.2] v 1.9 [1.3]; P = .44). CONCLUSION Patients receiving PROStep reported high understanding of symptoms and functional status from their oncology team, although this did not differ from controls. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF